Anbio Biotechnology Class A Ordinary Shares
NNNN - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$204.53M
Close$
$0.33
91.3% downside
Current Fair Value
91.3% downsideOvervalued by 91.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $204.53 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $0.16 |
| Beta | 5.26 |
| Outstanding Shares | 43,891,200 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 24.1 |
|---|---|
| PEG | -7.32 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Institutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.16%▲ 0.05% |
|---|---|
| Total Invested | $985,151▼ 23.65% |
| Investors Holding | 12▲ 4.00% |
About Anbio Biotechnology Class A Ordinary Shares
27 employees
CEO: Michael Lau
Anbio Biotechnology, established in 2021 and based in Frankfurt am Main, Germany, operates as a global supplier of in vitro diagnostics (IVD) products. The company's international footprint covers regions such as the European Union, Asia...